Business Context and Reporting Period
Company: McKesson Corporation
Filing Type: Form 8-K (Current Report)
Date of Report: February 13, 2017 (Event Date)
Reporting Period: Specific event reporting regarding debt issuance and legal proceedings.
Key Financial Metrics and Debt Issuance
The filing details the issuance of new debt instruments to raise capital for general corporate purposes and the repayment of maturing obligations.
- 2021 Euro Notes: €600,000,000 principal; 0.625% interest rate; matures August 17, 2021.
- 2025 Euro Notes: €600,000,000 principal; 1.500% interest rate; matures November 17, 2025.
- 2029 Sterling Notes: £450,000,000 principal; 3.125% interest rate; matures February 17, 2029.
- Net Proceeds: Approximately $1.8 billion after estimated expenses.
- Use of Proceeds: General corporate purposes and repayment of specific maturing debt totaling approximately $1.7 billion (including $500M 5.70% Notes, $700M 1.29% Notes, and €500M 4.50% Bonds).
Note: This filing does not provide revenue, profit, cash flow, or margin data for the reporting period.
Material Changes and Legal Contingencies
Debt Structure Change: The company has increased its unsecured indebtedness through the new Euro and Sterling Notes, which rank equally with existing unsecured debt. The notes include a make-whole redemption provision and a change-of-control repurchase obligation if ratings are downgraded below investment grade.
Legal Contingency: On January 31, 2017, a shareholder derivative complaint (Silverman v. McKesson Corporation et al.) was filed in the U.S. District Court for the Northern District of California. The complaint alleges violations of fiduciary duties regarding disclosures and internal controls related to the company's settlement with the Drug Enforcement Administration (DEA) and Department of Justice concerning suspicious order reporting practices for controlled substances. The complaint seeks unspecified damages, restitution, and disgorgement.
Guidance, Outlook, and Risks
Management Commentary: Management intends to use the net proceeds to refinance maturing debt and for general corporate purposes. The filing incorporates by reference the Underwriting Agreements and Officer's Certificate for full terms.
Risks:
- Legal Risk: Potential liability and reputational damage from the shareholder derivative suit regarding DEA/DOJ settlement disclosures.
- Financial Risk: Obligations to repurchase notes at 101% of principal plus accrued interest in the event of a change of control coupled with a credit rating downgrade.
- Covenants: Limitations on creating liens, sale-leaseback transactions, and mergers/consolidations.
Investor Verification Checklist
- Verify the exact exchange rate impact on the €1.2 billion and £450 million principal amounts when converting to USD for total debt load analysis.
- Review the specific terms of the "make-whole" premium in the Indenture to understand early redemption costs.
- Monitor the status of the Silverman v. McKesson Corporation lawsuit for updates on potential financial exposure or settlement terms.
- Confirm the repayment schedule of the maturing 2017 debt instruments to ensure liquidity coverage.
- Check current credit ratings from major agencies to assess the risk of triggering the change-of-control repurchase provision.